retatrutide como se usa for Weight Loss: TRIUMPH-1 Results, Cost, Insurance Retatrutide UK 2026: Phase 3

Many patients receive compounded GLP-1 medications in vials and feel unsure about injecting at home

In the STEP-1 trial published in The New England Journal of Medicine in 2021, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with overweight or obesity (Wilding et al., NEJM, 2021)

Read More Bloating on GLP1 medications like semaglutide and tirzepatide is caused by delayed gastric emptying and reduced gut motility

19 In the study, the researchers used a large electronic health record database to conduct a nationwide retrospective cohort study to assess the association of semaglutide with the incidence and recurrence of suicidal ideation compared with non-GLP1R agonist anti-obesity medications in individuals with overweight or obesity

If positive, they would add sleep apnoea to the list of obesity comorbidities in which retatrutide demonstrates clinical benefit strengthening the NICE cost-effectiveness case for NHS access by demonstrating benefit across multiple conditions simultaneously

At Batley Pharmacy, we understand that every patients journey is entirely unique